BioCryst Pharma (BCRX) Updates on non-Human BCX4430 PoC Study as Potential Ebola Virus Treatment
Tweet Send to a Friend
BioCryst Pharma (Nasdaq: BCRX) announced results from a proof-of-concept study of its broad spectrum antiviral BCX4430 for the treatment of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
